Ultragenyx Pharmaceutical Patent-Cliff Exposure & CMS Drug Spending Portfolio
Ultragenyx Pharmaceutical (Novato, CA): 2 reconciled FDA prescription therapies, $39.0M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Novato, CA |
| Reconciled FDA Portfolio Therapies | 2 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2034-01-01 |
| 2024 CMS Total Public Spend | $39.0M |
| 2024 Medicare Part D Spend | $5.6M |
| 2024 Medicaid Spend | $33.5M |
| California HCAI SB 17 Filings | 2 WAC filings (max 19.3% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Ultragenyx Pharmaceutical across sibling Meru public-data platforms.